The impact of multimorbidity and functional limitation on quality of life in patients with heart failure: A multi-site study

Sheila M Manemann; Erinn M Hade; Irina V Haller; Benjamin D Horne; Catherine P Benziger; Brent C Lampert; Kismet D Rasmusson; Veronique L Roger; Susan A Weston; Jill M Killian; Alanna M Chamberlain

doi:10.1111/jgs.18924

The impact of multimorbidity and functional limitation on quality of life in patients with heart failure: A multi-site study

J Am Geriatr Soc. 2024 Apr 18. doi: 10.1111/jgs.18924. Online ahead of print.

Authors

Affiliations

¹ Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
² Department of Population Health, NYU Grossman School of Medicine, New York, New York, USA.
³ Essentia Institute of Rural Health, Essentia Health, Duluth, Minnesota, USA.
⁴ Intermountain Medical Center Heart Institute, Salt Lake City, Utah, USA.
⁵ Division of Cardiovascular Medicine, Department of Medicine, Stanford University, Stanford, California, USA.
⁶ Heart and Vascular Center, Essentia Health, Duluth, Minnesota, USA.
⁷ Division of Cardiovascular Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
⁸ Epidemiology and Community Health Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
⁹ Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.

PMID: 38634747
DOI: 10.1111/jgs.18924

Abstract

Background: Multimorbidity and functional limitation are associated with poor outcomes in heart failure (HF). However, the individual and combined effect of these on health-related quality of life in patients with HF is not well understood.

Methods: Patients aged ≥30 years with two or more HF diagnostic codes and one or more HF-related prescription drugs from four U.S. institutions were mailed a survey to measure patient-centric factors including functional status (activities of daily living [ADLs]) and health-related quality of life (PROMIS-29 Health Profile). Patients with HF from January 1, 2013 to February 1, 2018 were included. Multimorbidity was defined as ≥2 non-cardiovascular comorbidities; functional limitation as any limitation in at least one of eight ADLs. Patients were categorized into four groups by multimorbidity (Yes/No) and functional limitation (Yes/No). We dichotomized the PROMIS-29 sub-scale scores at the median and calculated odd ratios for the four multimorbidity/functional limitation groups.

Results: A total of 3330 patients with HF returned the survey (response rate 31%); 3020 completed the questions of interest and were retained. Among these patients (45% female; mean age 73 [standard deviation: 12] years), 29% had neither multimorbidity nor functional limitation, 24% had multimorbidity only, 22% had functional limitation only, and 25% had both. After adjustment, having functional limitation only was associated with higher anxiety (odds ratio [OR]: 3.44, 95% confidence interval [CI]: 2.66-4.45), depression (OR: 3.11, 95% CI: 2.39-4.06), and fatigue (OR: 4.19, 95% CI: 3.25-5.40); worse sleep (OR: 2.14, 95% CI: 1.69-2.72) and pain (OR: 6.73, 95% CI: 5.15-8.78); and greater difficulty with social activities (OR: 9.40, 95% CI: 7.19-12.28) compared with having neither. Results were similar for having both multimorbidity and functional limitation.

Conclusion: Patients with only functional limitation have similar poor health-related quality of life scores as those with both multimorbidity and functional limitation, underscoring the important role that physical functioning plays in the well-being of patients with HF.

Keywords: functional limitation; heart failure; multimorbidity; quality of life.

Grants and funding

R01 HL120859/HL/NHLBI NIH HHS/United States